FDA Accepts BLA for RANLUSPEC by Lupin Limited
The FDA has accepted the Biologics License Application for RANLUSPEC, an anti-VEGF therapy.
Therapeutic Area
Therapeutic area intelligence for Anti-VEGF with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The AFLIPIO study will evaluate the intraocular pressure effects and anatomical repercussions of Aflibercept 0.07mL injections over 12 months.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.